-
Mashup Score: 10
Postoperative ctDNA detection is associated with early recurrence 1 year or earlier after curative-intent hepatectomy for CLM, and RAS/TP53 co-mutations result in a more than 3-fold increased risk for postoperative ctDNA positivity. This highlights the complementary effect of tumor tissue and circul …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @timnewhook19: A2-5. Nishioka et al, J Am Coll Surg, 2022 https://t.co/TjKKnkkAvm 📌Who is at highest risk for recurrence after curative…
-
-
Mashup Score: 2CtDNA in colorectal cancer - 2 year(s) ago
CRCTrialsChat@CRCTrialsChat257
Source: WakeletCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @CrcTrialsChat: If you missed last week's #CRCTrialsChat on ctDNA testing in CRC, here's the wakelet link https://t.co/M7vJn37KiH @Jeann…
-
-
Mashup Score: 5
Circulating tumor DNA (ctDNA), the tumor-derived cell-free DNA fragments in the bloodstream carrying tumor-specific genetic and epigenetic alterations, represents an emerging novel tool for minimal residual disease (MRD) assessment in patients with resected colorectal cancer (CRC). For many decades, precise risk-stratification following curative-intent colorectal surgery has remained an enduring…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet-
#CRCTrialsChat Awesome open access review by @aparna1024 @ @doctorC369 @anup_kasi https://t.co/F57UcN4ZKM
-
-
Mashup Score: 9
Discover & share this Changemaker High School GIF with everyone you know. GIPHY is how you search, share, discover, and create GIFs.
Source: GIPHYCategories: Hem/Oncs, Latest HeadlinesTweet-
📌Pts with stage IIA⬇️risk colon (non-rectal) cancer & not recommended to have adj chemo by their doctor are eligible 📌Must randomize before 60d from sx 📌@GuardantHealth REVEAL ct🧬assay used 📌@NRGOncology GI005 open & accruing in 🇺🇸 &🇨🇦 #CRCTrialsChat https://t.co/F7TrsVn1OG https://t.co/6KzcZVSq84
-
-
Mashup Score: 3Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study | OncologyPRO - 2 year(s) ago
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Source: oncologypro.esmo.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DrBonillaOnc: @agrothey @doctorC369 @JeanneTie @MyriamChalabi was ctDNA used in NICHE-2? https://t.co/p9QknnuK33 #crctrialschat https:/…
-
-
Mashup Score: 6
Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, explains the rationale for initiating the Phase III BREAKWATER (NCT046…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
1L BREAKWATER Enrolling now🔥 Phase III trial with patients randomized to E+C alone or E+C+FOLFOX or control (FOLFOX/FOLFOXIRI/CAPOX+Bev) More intro about the trial from Dr @skopetz https://t.co/UuHivtd3Q5 📌To enroll, patients should not have started any tx #CRCTrialsChat https://t.co/9w0vZ9eros
-
-
Mashup Score: 10Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients - PubMed - 2 year(s) ago
Patients with resectable BRAF-mut CRLM are rare among patients selected for surgery and more commonly present with multiple synchronous tumors. BRAF mutation is associated with worse prognosis; however, long-term survival is possible and associated with node-negative primary tumors, CEA ≤ 200 μg/L a …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
1 major study by @sepideh_gholami et al. 👀 at >4k pts s/p 🔪 for liver mets ➡️Median OS 81 mo BRAF-wt vs 40 mo BRAF mut ➡️Node +ve primary, ≥4 CRLM, and +ve liver margin = worse RFS ➡️BUT, long term survival w/ 🔪 is possible ➡️https://t.co/W4UgZugOz1 2/n #CRCTrialsChat
-
-
Mashup Score: 4Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: An updated meta-analysis - PubMed - 2 year(s) ago
This meta-analysis confirms that BRAF mutations impair both OS and RFS following liver surgery. Therefore, BRAF mutational status should probably be included in further prognostic scores for the assessment of the expected clinical outcomes following surgery for CRLM.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#CRCTrialsChat #BRAF 1/n Surgery 🔪 for BRAF mutated CRLM? ➡️BRAF mutation alone does not preclude surgical resection ➡️Multiple studies show worse OS & shorter PFS ➡️Also, BRAF patients have higher local & distant recurrence rates than BRAF WT https://t.co/Wxcu96cmnr
-
-
Mashup Score: 0
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Upcoming/open at MGH, MDACC, and other sites Erasca ERKi added to E+C Beacon. Allows prior E+C exposure INTRINSIC trial from Genentech CDKi https://t.co/6acPNvn6zs 35 places in the world Other: BMD ERKi Ulixertinib EAP available from @xcures_platform add to E+C #CRCTrialsChat
-
-
Mashup Score: 0The Cancer News Daily - 2 year(s) ago
The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Cancer News Daily! https://t.co/K1QIRWR6Lt Thanks to @NobelPrize @FightCRC @SU2C #crctrialschat #clinicaltrials
-
A2-5. Nishioka et al, J Am Coll Surg, 2022 https://t.co/TjKKnkkAvm 📌Who is at highest risk for recurrence after curative intent hepatectomy for CRC Liver mets? Important question.. Answer may help decide treatment plan Biomarkers? CEA? ctDNA? #CRCTrialsChat #CRCSM #CRLM